Physician profile
Rose A Cunningham
NPI 1992026827
$473.27
in general payments reported to CMS, 2019-2025
10 companies · $212 in 2025
The $212 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $58.68 · 2022: $127 · 2023: $44.29 · 2024: $31.47 · 2025: $212.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $287.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $287.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $158.33 | 2021-2024 | Xifaxan |
| Novo Nordisk INC | $80.39 | 2025 | Wegovy, Ozempic, Rybelsus |
| Alkermes, INC. | $55.35 | 2021-2023 | Vivitrol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $51.74 | 2025 | Caplyta |
| Biohaven Pharmaceutical Holding Company LTD. | $35.55 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $22.87 | 2025 | Airsupra |
| Exact Sciences Corporation | $20.13 | 2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $19.84 | 2025 | |
| Hartmann USA, INC. | $16.69 | 2025 | Zetuvit Plus 10x10 P10 |
| Otsuka America Pharmaceutical, INC. | $12.38 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rose Cunningham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.